|
RBBP5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.57199999578839E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.43679999961866E-07 |
| Normal-vs-Stage2 |
1.143360E-03 |
| Normal-vs-Stage3 |
1.09399999947968E-07 |
| Normal-vs-Stage4 |
2.60539999996645E-06 |
| Stage1-vs-Stage2 |
6.511800E-01 |
| Stage1-vs-Stage3 |
2.518800E-01 |
| Stage1-vs-Stage4 |
4.004200E-01 |
| Stage2-vs-Stage3 |
2.441400E-01 |
| Stage2-vs-Stage4 |
3.163000E-01 |
| Stage3-vs-Stage4 |
9.752800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.27800000476941E-08 |
| Normal-vs-AfricanAmerican |
5.315800E-02 |
| Normal-vs-Asian |
2.21239999999012E-05 |
| Caucasian-vs-AfricanAmerican |
9.004300E-02 |
| Caucasian-vs-Asian |
8.253400E-01 |
| AfricanAmerican-vs-Asian |
9.863900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.20950000307374E-08 |
| Normal-vs-Female |
2.50819999991769E-07 |
| Male-vs-Female |
1.693800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.14000000004133E-06 |
| Normal-vs-Age(41-60Yrs) |
9.57079999697186E-08 |
| Normal-vs-Age(61-80Yrs) |
3.51310000001881E-06 |
| Normal-vs-Age(81-100Yrs) |
3.482400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.365000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.542200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.823200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.252200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.082800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.317800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.933640E-02 |
| Classical-VS-Follicular |
1.211980E-01 |
| Classical-VS-Other |
1.028990E-01 |
| Classical-VS-Normal |
3.17739999999844E-06 |
| Tall-VS-Follicular |
3.617400E-01 |
| Tall-VS-Other |
4.428000E-01 |
| Tall-VS-Normal |
3.75740000002622E-07 |
| Follicular-VS-Other |
3.128200E-01 |
| Follicular-VS-Normal |
2.15879999998503E-06 |
| Other-VS-Normal |
1.564420E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.63380000031788E-07 |
| Normal-vs-N1 |
1.79950000012141E-07 |
| N0-vs-N1 |
1.256630E-01 |
|
|
